# Finbot Hard Review Summary

Generated: `2026-05-11T00:32:19+08:00`

Reviewer: `Worker A / Codex`

Boundary: research-only. This artifact does not provide investment advice, target-price advice, trade signals, broker actions, automatic trading, position sizing, or a production watchlist.

## Inputs

- `/tmp/ChatgptREST-review/paperclip-review-20260510/FINBOT/latest_8h`
- `/tmp/ChatgptREST-review/paperclip-review-20260510/PRO_ANSWER_DIGEST.md`
- `/tmp/ChatgptREST-review/paperclip-review-20260510/NEXT_EXECUTION_PLAN.md`

Pro and next-plan constraints used for this review:

- Pro flagged medium residual risk because the package has internal artifacts but lacks external integration proofs and runtime validation.
- The next plan says Finbot must stay capability-lab/research-only and must not claim production readiness.
- The next plan requires claim-level primary/authority evidence before any high-tier classification.

## Method

Each selected case was checked against a five-part chain:

`Claim -> Evidence file -> Source -> Timestamp -> Reviewer`

Status meanings:

- `hard_reviewed_park`: chain is inspectable enough to remain in the research queue, but not enough for high-quality classification.
- `hard_reviewed_reject`: chain is inspectable and fails due to evidence mismatch or missing authority.
- `high_quality`: not awarded in this pass; it requires a primary/authority source trace point, ticker-aligned evidence, timestamped source artifact, counter-evidence, and a reviewer decision.

## Selected Cases

| Case | Ticker | Evidence ID | Verdict | Reason |
| --- | --- | --- | --- | --- |
| `OA-12-03-pltr-source-system-gaps-to-enable-next` | PLTR | `EV-12-PLTR` | `hard_reviewed_park` | Evidence ID is ticker-aligned and appears in the top queue, but the latest input only exposes summary-level source binding; primary-source trace points are not present in the provided copy. |
| `OA-12-02-anet-policy-driven-china-supply-chains` | ANET | `EV-12-ANET` | `hard_reviewed_park` | Evidence ID is ticker-aligned, but the source mix includes candidate-to-enable China/A-share routes and lacks case-specific primary-source trace text in the provided copy. |
| `OA-11-03-panw-security-platform-consolidation` | PANW | `EV-11-PANW` | `hard_reviewed_park` | Evidence ID is ticker-aligned, but the cycle 11 source chain leans on local ledgers and candidate policy/ownership context; primary issuer evidence is not trace-bound in the provided copy. |
| `OA-X139-pltr-china-anti-dumping-policy-exposure` | PLTR | `EV-05-CROX` | `hard_reviewed_reject` | Evidence ID is not ticker- or theme-aligned; it points to a CROX/consumer case while the claim is PLTR/policy exposure. |
| `OA-X140-rddt-boring-infrastructure-rollup-alpha` | RDDT | `EV-05-ELF` | `hard_reviewed_reject` | Evidence ID is not ticker- or theme-aligned; it points to an ELF/brand-channel source while the claim is RDDT/infrastructure rollup. |

Current count from this pass:

- Hard-reviewed cases: `5`
- High-quality cases: `0`
- Parked: `3`
- Rejected: `2`

## Weak Case Handling

Rejected cases should not be reintroduced by score alone. They can only return as new cases with a new evidence ID that is ticker-aligned and source-bound.

Parked cases can continue only as research tasks. They need a bound primary source, a counter-source, a source timestamp, and a reviewer decision before any high-quality label.

## Path To 10 Hard-Reviewed / 5 High-Quality

Next five hard-review candidates:

1. `OA-12-01-tsm-a-share-official-disclosure-backlog`
2. `OA-11-01-crwd-ai-attack-surface`
3. `OA-11-02-zs-identity-and-zero-trust-spend`
4. `OA-10-03-ferg-specialty-contractor-rollups`
5. `OA-02-01-vrt-data-center-power-bottleneck`

Promotion gate for five high-quality cases:

1. Ticker-aligned evidence ID appears in `07_alpha_qualified_casebook.md` and, if top-ranked, in `06_top_surprising_opportunities.md`.
2. Source basis includes at least one primary/authority source marked `workflow_verified` or a clearly timestamped authority artifact.
3. The exact source artifact and trace point are available to the next reviewer, not only an evidence ID.
4. Risk/reversal row includes an explicit invalidation trigger and at least one counter-evidence route.
5. Human review action is framed as continued research or retirement only, with no advice/trading/watchlist output.

Until those gates pass, the honest FINBOT label is: `research_queue_hard_review_in_progress`.
